KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBT Margin (2018 - 2025)

Historic EBT Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 1.63%.

  • BioNTech SE's EBT Margin fell 111200.0% to 1.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.23%, marking a year-over-year decrease of 59200.0%. This contributed to the annual value of 24.63% for FY2024, which is 556900.0% down from last year.
  • BioNTech SE's EBT Margin amounted to 1.63% in Q3 2025, which was down 111200.0% from 154.41% recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's EBT Margin ranged from a high of 85.2% in Q4 2021 and a low of 626.11% during Q2 2024
  • For the 5-year period, BioNTech SE's EBT Margin averaged around 35.14%, with its median value being 44.84% (2023).
  • As far as peak fluctuations go, BioNTech SE's EBT Margin crashed by -3803100bps in 2024, and later surged by 4717000bps in 2025.
  • BioNTech SE's EBT Margin (Quarter) stood at 85.2% in 2021, then decreased by -13bps to 74.16% in 2022, then tumbled by -40bps to 44.84% in 2023, then tumbled by -44bps to 25.31% in 2024, then plummeted by -94bps to 1.63% in 2025.
  • Its EBT Margin was 1.63% in Q3 2025, compared to 154.41% in Q2 2025 and 243.65% in Q1 2025.